Overview
This study is to explore the safety, tolerability, pharmacokinetics, and preliminary efficacy of BGM-2121 in adult patients with advanced solid tumors.
Eligibility
Inclusion Criteria:
- With either gender aged ≥ 18 years,
- Has a confirmed diagnosis of advanced solid tumor(s),
- The subject has received and failed standard-of-care anti-cancer therapy
- Has at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST)
- ...
Exclusion Criteria:
- Has any ongoing toxicity from previous anti-cancer treatments
- Has signs or symptoms of end-stage organ failure, major chronic illnesses other than cancer(s)
- History of another primary malignancy within the last three years
- ...
